{"analyses":[{"ciLowerLimit":"-36.3","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"24.3","groupIds":["OG000","OG001"],"nonInferiorityComment":"Two-sided Cochran-Mantel-Haenszel test for the CBR was performed, which is used for testing zero effect or \"equivalence\" between treatments. A two-sided significance level of 0.05 will be considered for the test.","nonInferiorityType":"EQUIVALENCE","pValue":"0.702","paramType":"Risk Difference (RD)","paramValue":"-6.0","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"}]}],"title":"Stable Disease (SD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"}]}],"title":"Partial Response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"2"}]}],"title":"Combined total CR + PR + SD"}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"description":"CBR is defined as the percentage of patients with advanced or metastatic cancer who have achieved CR (disappearance of all target lesions), PR (\\>=30% decrease in the sum of the longest diameter of target lesions), and stable disease (SD) (neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum diameters of target lesions) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; CBR = CR + PR + SD.\n\nWill also assess CBR in patients stratified by PD-L1 expression levels in the tumor microenvironment.","groups":[{"description":"Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.\n\nAtezolizumab: Given IV\n\nGlycosylated Recombinant Human Interleukin-7: Given IM","id":"OG000","title":"Group 1 (CYT107, Atezolizumab)"},{"description":"Patients receive atezolizumab on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.\n\nAtezolizumab: Given IV","id":"OG001","title":"Group 2 (Atezolizumab)"},{"description":"Patients were not randomized; they were assigned to the experimental arm treatment (atezolizumab + CYT107). Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.\n\nAtezolizumab: Given IV\n\nGlycosylated Recombinant Human Interleukin-7: Given IM","id":"OG002","title":"Safety Run in Phase"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The PD-L1 assay produced no data due to expired antibody. Stratification by PD-L1 expression levels in the tumor microenvironment cannot be reported.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Clinical Benefit Rate (CBR) Measured by RECIST v1.1","type":"SECONDARY","unitOfMeasure":"Participants"}